News

19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX),… Read More »Preliminary Results for the Year Ended 31 December 2023 

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of exclusive, worldwide license to Tolimidone, Phase… Read More »Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option 

29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing… Read More »Interim results for the six months ended 30 June 2023 

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed… Read More »Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement 

6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed… Read More »Results of Appeal of Delisting Determination